Ascendis Pharma A (ASND) Cash & Current Investments (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Cash & Current Investments data on file, last reported at $670.6 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments rose 23.1% year-over-year to $670.6 million; the trailing twelve-month figure through Mar 2026 stood at $670.6 million (up 23.1% YoY), and the FY2025 full-year result was $1.0 billion, up 32.09% from the prior year.
• Cash & Current Investments eased to $670.6 million in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $1.0 billion in Q4 2025 to a low of $278.6 million in Q2 2024.
• A 5-year average of $589.4 million and a median of $559.2 million in 2025 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments tumbled 40.36% in 2023 and jumped 100.74% in 2025, its largest moves.
• Tracing ASND's Cash & Current Investments over 5 years: stood at $471.1 million in 2022, then retreated by 10.43% to $421.9 million in 2023, then soared by 79.86% to $758.9 million in 2024, then jumped by 33.79% to $1.0 billion in 2025, then plunged by 33.95% to $670.6 million in 2026.
• Business Quant data shows ASND's Cash & Current Investments at $670.6 million in Q1 2026, $1.0 billion in Q4 2025, and $630.2 million in Q3 2025.